Related Experiment Video

Updated: Apr 12, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.8K

Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms

Carissa R Moore1, Shanique Ke Edwards2, Ping Xie3

  • 1Department of Cell Biology and Neuroscience, New Jersey, USA.

Journal of Cancer Science & Therapy
|May 12, 2015
PubMed

Insights

Tumor suppressor TRAF3 is crucial in B cell lymphomas. Targeting its downstream pathways offers new therapeutic strategies for treating B cell neoplasms like lymphoma and multiple myeloma.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • B cell neoplasms represent over half of all blood cancers, with many types currently incurable.
  • Identifying novel genetic risk factors and oncogenic signaling pathways is critical for developing effective therapeutic strategies.
  • TRAF3 (TNF receptor-associated factor 3) has been identified as a tumor suppressor in B lymphocytes.

Purpose of the Study:

  • To investigate the role of TRAF3 signaling mechanisms in B cells.
  • To develop novel therapeutic strategies targeting TRAF3 downstream signaling pathways in B cell neoplasms.
  • To present translational data demonstrating the therapeutic potential of targeting TRAF3 in B lymphoma and multiple myeloma.

Main Methods:

  • Investigated TRAF3 signaling mechanisms in B cells.
  • Analyzed TRAF3 deletions and inactivating mutations in human B cell malignancies.
  • Developed and evaluated therapeutic strategies targeting TRAF3 downstream signaling.

Main Results:

  • TRAF3 inactivation leads to prolonged survival of mature B cells and spontaneous B lymphoma development in mice.
  • TRAF3 alterations are frequent in human B cell chronic lymphocytic leukemia, splenic marginal zone lymphoma, mantle cell lymphoma, multiple myeloma, Waldenström's macroglobulinemia, and Hodgkin lymphoma.
  • Translational data show therapeutic potential in targeting TRAF3 downstream signaling pathways.

Conclusions:

  • TRAF3 functions as a tumor suppressor in B lymphocytes.
  • Targeting TRAF3 downstream signaling pathways presents a promising therapeutic avenue for B cell neoplasms.
  • Further research into TRAF3 pathways could lead to improved treatments for intractable B cell malignancies.
Keywords:
AD 198B lymphomaMCCMultiple myelomaNF-κB2Sox5TRAF3

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

930
Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

301

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K